Information Provided By:
Fly News Breaks for April 25, 2017
PRGO, MYL, TEVA, MNK
Apr 25, 2017 | 10:47 EDT
This morning's Q1 results from Novartis' (NVS) Sandoz division highlight the difficult U.S. generic price environment, Wells Fargo analyst David Maris tells investors in a research note. Sandoz experienced pricing erosion of 8% in the quarter, which represents the largest negative impact from pricing in recent quarters, Maris writes. He expects the negative U.S. pricing environment to impact including Mallinckrodt (MNK), Teva (TEVA), Mylan (MYL) and Perrigo (PRGO). Maris remains cautious on the pricing environment for generics.
News For MNK;TEVA;MYL;PRGO From the Last 2 Days
There are no results for your query MNK;TEVA;MYL;PRGO